Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| With our size and scale and with the number of laboratories we touch, there are, I would say, really nice opportunities to further engrain ourselves within our customers and help them on a number of items |
| We're now, I think, testing approximately 90% of all HRD patients in Spain, which has been a great success |
| We are pleased to have an incredibly strong end to the year |
| The combined nature of these items and the natural operating leverage in the business from strong revenue growth will further our path to profitability in the next two-plus years |
| We're proud of our performance, which we believe reflects our continued ability to execute on our vision and the opportunity ahead |
| We are confident in our medium-term path to profitability |
| Strength in North America and Asia Pacific highlighted geographic outperformance in the quarter, offsetting a slight moderation in Latin America, which had an overall strong 2023 |
| This record number of analyses represent a remarkable 27% year-over-year growth when excluding COVID-related volume |
| Excluding COVID-related volume, platform analyses grew a healthy 24% year-over-year in the period |
| And so, I'm incredibly encouraged around the early interest and now it's on us to turn that activity and interest into revenue, right? And so, I would say, again, this will be something that plays out primarily for us in the second half of this year, but will move into '25 as well |
| We've had very good labor absorption |
| SOPHiA's success stands on our ability to delight customers and continue driving more and more usage of our platform |
| But overall, I would say, things are progressing quite well and I'm incredibly proud of the hard work of the team |
| I'm proud to say that we delivered in each of these three areas |
| I'm pleased to share that despite the challenging macro environment, SOPHiA GENETICS delivered strong performance in the fourth quarter, continuing our commitment to sustainable growth |
| Solid tumor revenue grew above company average in 2023 and HRD was a major driver with over 150% revenue growth during the period |
| We're pleased to see both existing and new customers adopt SOPHiA DDM for Solid Tumor applications |
| I am incredibly proud of this outcome as we have now outperformed our medium-term guidance for an entire year |
| In summary, 2024 is an exciting year from our liquid biopsy capabilities, to our world-class solid tumor applications, to the momentum we are building in the U.S., we are well equipped for 2024, and as we continue on our path to profitability in the next two-plus years |
| So, I think relative to the initial opportunity in ovarian, we're making very good progress |
| Net dollar retention for the year improved to 130%, up 2,800 basis points from 102% in 2022 |
| Based on our current commercial pipeline, we're confident that these new launches will deliver long-term value to our business |
| This has been quite a good result for us in Europe as well, if you think about IVDR |
| We officially launched MSK-ACCESS powered with SOPHiA DDM in December and have been pleased to see strong demand for this application in the market |
| I think as mentioned, we've had a -- we've demonstrated a proven ability to expand within our existing customers, which makes the announcement that we had today that we're adding 35 new core genomics customers |
| Excluding COVID-related volume, platform analyses grew at a strong 27% year-over-year in the period |
| But we just wanted to call it out this year relative to some of those dynamics that we're seeing, right? And so, ultimately, we feel good about that |
| I'll remain encouraged with respect to continued expansion opportunities moving forward |
| So, it also benefits us |
| But frankly, overall, we feel quite confident on our continued ability to drive GM expansion |
| Statement |
|---|
| Of note, clinical revenue fell in line within our internal plan as consumption trends played out as expected in the second half |
| On a reported basis, share-based compensation was also a notable headwind broadly |
| Two, we also expect a very modest headwind to 2024 reported revenues related to a ceasing of COVID-related contribution |
| Lastly, total cash burn for the full year 2023 was $55.4 million compared to $86.7 million in the prior year, down 36% |
| Because the ability to maintain your own pipelines or multiple district pipelines and approaches, I think will be quite a challenge |
| One, we currently contemplate that exchange rates will remain highly volatile, and as such, we are anticipating a moderate negative impact to reported results in 2024 |
| FX was a notable headwind in the period, particularly impacting R&D expenditures |
| So, I think the pressure on our customers essentially to move to a validated platform will just be higher |
| We would attribute two key factors to a more conservative stance as we approach 2024 revenue guidance |
| Of note, below the line this quarter, we did have a significant charge related to foreign exchange losses |
| And so, I think that solution, again, relative to tissue is a bit more complex, right? And I think on our end, both given it's a tumor-normal solution and so that means sample acquisition is a bit more challenging, but also just the workflow for the customer |
| We have taken the required actions to expedite that goal and remain obsessed with capital efficiency |
| This is despite excellent new customer momentum exhibited in 2023 |
| Operating loss for the fourth quarter of 2023 was $18.9 million compared to $15.1 million in the fourth quarter of 2022 |
| Turning to operating loss |
| We currently expect adjusted operating loss to fall between $45 million and $50 million |
| But given our lack of historical context with many of these businesses, right, again, you well know the market had been dominated by one or two players for the better part of the last decade |
| This is despite a challenging comp in the first quarter due to the remaining prior year Microsoft credit |
| So, we have very little contribution |
| And so, I would say, given those moving parts, we have waited to sort of better understand where those pieces will fit in, in terms of overall mix |
Please consider a small donation if you think this website provides you with relevant information